Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F),...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Acquir Immune Defic Syndr
Main Authors: Pozniak, Anton, Arribas, Jose R., Gathe, Joseph, Gupta, Samir K., Post, Frank A., Bloch, Mark, Avihingsanon, Anchalee, Crofoot, Gordon, Benson, Paul, Lichtenstein, Kenneth, Ramgopal, Moti, Chetchotisakd, Ploenchan, Custodio, Joseph M., Abram, Michael E., Wei, Xuelian, Cheng, Andrew, McCallister, Scott, SenGupta, Devi, Fordyce, Marshall W.
Format: Artigo
Sprog:Inglês
Udgivet: JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Fag:
Clinical Science
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804743/
https://ncbi.nlm.nih.gov/pubmed/26627107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000000908
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker